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Background
Brachyury is a tumor-associated antigen and transcrip-
tion factor that drives the epithelial-to-mesenchymal
transition in human carcinomas. This Phase I study
assessed whether patients with advanced cancer or chor-
doma, a rare tumor of the notochord that overexpresses
brachyury, can elicit brachyury-specific T cell responses
following vaccination with MVA-Brachyury-TRICOM.
Methods
Patients with advanced cancer (n=25) or chordoma
(n=13) enrolled on a Phase I clinical trial of MVA-bra-
chyury vaccine (NCT02179515). Dose escalation was per-
formed following 3+3 design in 3 dose levels
(DL1=2×108, DL2=4×108, DL3=8×108 plaque forming
units, with vaccine administered in 3 cycles every 4
weeks). After safety was established, expansion cohorts
were enrolled at DL2 and DL3 to compare brachyury-
specific-T cell responses. Peripheral blood mononuclear
cells from pre- and post-vaccination (~day 29, 57, 85,
and 176) were stimulated with brachyury or HLA (nega-
tive control) 15-mer peptide pools and analyzed for bra-
chyury-specific-T cell responses by intracellular staining
of CD4 and CD8 T-lymphocytes for the cytokines IFN-g,
TNF, and IL-2, and the degranulation marker CD107a.
Results
In total, 3 patients enrolled on DL1, 17 on DL2, and 18
on DL3. On DL2 and DL3, 1 and 2 patients, respectively,
were not evaluable for safety or immune responses and
replaced. MVA-brachyury was well tolerated with no
dose limiting toxicities. The maximal tolerated dose was
not reached. Two deaths occurred on study, both due to
complications of rapid disease progression, unrelated to
vaccine. Two other serious adverse events (AEs)
occurred, a hip fracture after a fall and a colonic obstruc-
tion due to disease progression. No serious adverse event
was related to vaccine. AEs occurring in >2 unique
patients included diarrhea (7.9%), fever (18%), flu-like
symptoms (34%), and injection site reaction (74%). One
grade 3 adverse event, diarrhea, was related to vaccine,
and resolved without intervention after 48 hours. All
other adverse events related to vaccine were grade 1 or 2
with short duration. Immune responses were analyzed in
29 patients. Brachyury-specific T cell responses were
observed at each dose level: 66% (2/3) of patients at DL1,
80% (12/15) at DL2, and 90% (10/11) at DL3. At DL2 and
DL3, ~80% of the patients that developed brachyury-spe-
cific-T cells demonstrated responses in both CD4 and
CD8 T-lymphocytes.
Conclusions
These findings show for the first time that advanced
cancer patients can be safely immunized with an MVA-
based vaccine targeting brachyury, and can develop bra-
chyury-specific T cell immune responses. These results
warrant further studies using this vaccine in additional
cohorts of cancer patients.
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